# NUVB catalysts: Nuvation Bio Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/nuvb/catalysts

> Nuvation Bio Inc. (NUVB) has 11 upcoming catalysts. The next is the IBTROZI (taletrectinib) PDUFA date, January 4, 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for NUVB?

Nuvation Bio Inc. (NUVB) has 11 upcoming catalysts. The next is the IBTROZI (taletrectinib) PDUFA date, January 4, 2027. Press release filed with the SEC (EX-99): "In September 2026, Nuvation Bio announced that the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for IBTROZI, four months ahead of the January 4, 2027, target action date." [Calendar and source filings](https://sec-api.dev/companies/nuvb/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001193125-26-447321, https://www.sec.gov/Archives/edgar/data/1811063/000119312526447321/d371447dex991.htm (retrieved 2026-11-12). Last confirmed 2026-11-04. Cite: https://sec-api.dev/companies/nuvb/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Nuvation Bio Inc. |
| Ticker | NUVB (NYSE) |
| SEC CIK | 1811063 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/nuvb |

## Cash runway

Cash $663.4M as of 2026-09-30; quarterly burn $38.6M; about 51.6 months of runway at that rate (XBRL company facts, accession 0001193125-26-447238).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Mar 2022 | [NUV-868 trial start](https://sec-api.dev/pdufa/nuv-868) | NUVB | advanced solid tumors to determine a maximum tolerated dose | completed | "In March 2022, we initiated a Phase 1 monotherapy dose escalation study of NUV-868 in patients with advanced solid tumors to determine a maximum tolerated dose." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1811063/000095017025034903/nuvb-20241231.htm)) |
| June 7, 2024 | [IBTROZI (taletrectinib) NDA/BLA submission](https://sec-api.dev/pdufa/taletrectinib) | NUVB |  | completed | "These pooled results utilized a June 7, 2024 data cut off and were used to support our U.S. NDA submission that was submitted in October 2024." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1811063/000095017025034903/nuvb-20241231.htm)) |
| Aug 2024 | [INDIGO (vorasidenib) FDA approval](https://sec-api.dev/pdufa/vorasidenib) | NUVB | IDH1- or IDH2-mutant grade 2 astrocytoma or oligodendroglioma | completed, approved | "In August 2024, the U.S. FDA approved Servier Pharmaceutical's vorasidenib for the treatment of IDH1- or IDH2-mutant grade 2 astrocytoma or oligodendroglioma following surgery." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1811063/000119312526009826/d947742dex993.htm)) |
| Oct 2024 | [IBTROZI (taletrectinib) NDA/BLA submission](https://sec-api.dev/pdufa/taletrectinib) | NUVB | with advanced ROS1+ NSCLC | completed | "Based on pooled results of the TRUST-I and TRUST-II studies, we submitted a New Drug Application ("NDA") for taletrectinib to the U.S. FDA in October 2024 for the treatment of patients with advanced ROS1+ NSCLC (line agnostic, full approval)." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1811063/000095017025065712/nuvb-20250331.htm)) |
| Dec 2024 | [IBTROZI (taletrectinib) NDA/BLA acceptance](https://sec-api.dev/pdufa/taletrectinib) | NUVB |  | completed | "In December 2024, the U.S FDA accepted and granted Priority Review to the Companys NDA for taletrectinib for advanced ROS1+ NSCLC (line agnostic, full approval)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1811063/000119312525048529/d910737dex991.htm)) |
| March 6, 2025 | [Nuvation Bio Inc. earnings report](https://sec-api.dev/companies/nuvb/catalysts) | NUVB |  | completed | "Nuvation Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1811063/000119312525048529/d910737dex991.htm)) |
| May 7, 2025 | [Nuvation Bio Inc. earnings report](https://sec-api.dev/companies/nuvb/catalysts) | NUVB |  | completed | "Nuvation Bio Reports First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1811063/000119312525114908/d905090dex991.htm)) |
| June 11, 2025 | [IBTROZI (taletrectinib) FDA approval](https://sec-api.dev/pdufa/taletrectinib) | NUVB |  | completed, approved | "On June 11, 2025, we announced that the FDA approved IBTROZI (taletrectinib) for the treatment of adult patients with locally advanced or metastatic ROS1+ non-small cell lung cancer (NSCLC)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1811063/000119312525174954/d909051dex991.htm)) |
| June 11, 2025 | [IBTROZI (taletrectinib) primary completion](https://sec-api.dev/pdufa/taletrectinib) | NUVB | Non Small Cell Lung Cancer | completed | "NCT04919811 (Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-06-11 (ACTUAL); Lead Sponsor Nuvation Bio Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04919811)) |
| June 11, 2025 | [Ibtrozi (taletrectinib adipate) FDA approval](https://sec-api.dev/pdufa/taletrectinib-adipate) | NUVB | To treat locally advanced or metastatic ROS1-positive non-small cell lung cancer | completed, approved | "Ibtrozi \| taletrectinib \| 6/11/2025 \| To treat locally advanced or metastatic ROS1-positive non-small cell lung cancerDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025)) |
| June 23, 2025 | [IBTROZI (taletrectinib) PDUFA date](https://sec-api.dev/pdufa/taletrectinib) | NUVB | advanced ROS1+ NSCLC | completed, approved | "The PDUFA goal date of June 23, 2025 positions Nuvation Bio to commercialize taletrectinib in the U.S., if approved, in mid-2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1811063/000119312525114908/d905090dex991.htm)) |
| June 23, 2025 | [Nuvation Bio Inc. PDUFA date](https://sec-api.dev/companies/nuvb/catalysts) | NUVB |  | scheduled | "NDA with Priority Review designation and assigned a PDUFA target action date of June 23, 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1811063/000095017025034903/nuvb-20241231.htm)) |
| August 7, 2025 | [Nuvation Bio Inc. earnings report](https://sec-api.dev/companies/nuvb/catalysts) | NUVB |  | completed | "Nuvation Bio Reports Second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1811063/000119312525174954/d909051dex991.htm)) |
| November 3, 2025 | [Nuvation Bio Inc. earnings report](https://sec-api.dev/companies/nuvb/catalysts) | NUVB |  | completed | "Nuvation Bio Reports Third Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1811063/000119312525262576/d21938dex991.htm)) |
| January 11, 2026 | [Nuvation Bio Inc. earnings report](https://sec-api.dev/companies/nuvb/catalysts) | NUVB |  | completed | "Nuvation Bio Reports Preliminary Fourth Quarter and Full Year 2025 Financial Results and Provides 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1811063/000119312526009826/d947742dex991.htm)) |
| March 2, 2026 | [Nuvation Bio Inc. earnings report](https://sec-api.dev/companies/nuvb/catalysts) | NUVB |  | completed | "Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1811063/000119312526085474/d15383dex991.htm)) |
| May 4, 2026 | [Nuvation Bio Inc. earnings report](https://sec-api.dev/companies/nuvb/catalysts) | NUVB |  | completed | "Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1811063/000119312526204056/d132166dex991.htm)) |
| August 6, 2026 | [Nuvation Bio Inc. earnings report](https://sec-api.dev/companies/nuvb/catalysts) | NUVB |  | completed | "Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1811063/000119312526336751/d261840dex991.htm)) |
| Sep 2026 | [IBTROZI (taletrectinib) label expansion decision](https://sec-api.dev/pdufa/taletrectinib) | NUVB |  | completed, approved | "In September 2026, Nuvation Bio announced that the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for IBTROZI, four months ahead of the January 4, 2027, target action date." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1811063/000119312526447321/d371447dex991.htm)) |
| September 16, 2026 | [Ibtrozi (taletrectinib adipate) label expansion decision](https://sec-api.dev/pdufa/taletrectinib-adipate) | NUVB |  | completed, approved | "NDA219713 SUPPL-4 (Efficacy): submission_status AP, submission_status_date 20260916, review_priority STANDARD; sponsor_name NUVATION; product IBTROZI (TALETRECTINIB ADIPATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA219713%22)) |
| November 4, 2026 | [Nuvation Bio Inc. earnings report](https://sec-api.dev/companies/nuvb/catalysts) | NUVB |  | completed | "Nuvation Bio Reports Third Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1811063/000119312526447321/d371447dex991.htm)) |
| January 4, 2027 | [IBTROZI (taletrectinib) PDUFA date](https://sec-api.dev/pdufa/taletrectinib) | NUVB |  | scheduled | "In September 2026, Nuvation Bio announced that the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for IBTROZI, four months ahead of the January 4, 2027, target action date." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1811063/000119312526447321/d371447dex991.htm)) |
| December 2028 | [Safusidenib primary completion](https://sec-api.dev/pdufa/safusidenib) | NUVB | Glioma; Astrocytoma, Grade IV; IDH1-mutant Glioma | scheduled | "NCT05303519 (SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12-01 (ESTIMATED); Lead Sponsor Nuvation Bio Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05303519)) |
| Dec 2028 to Mar 2029 | [Safusidenib topline data readout](https://sec-api.dev/pdufa/safusidenib) | NUVB | Glioma; Astrocytoma, Grade IV; IDH1-mutant Glioma | scheduled | "NCT05303519 (SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12-01 (ESTIMATED); Lead Sponsor Nuvation Bio Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05303519)) |
| January 2029 | [IBTROZI (taletrectinib) primary completion](https://sec-api.dev/pdufa/taletrectinib) | NUVB | Non Small Cell Lung Cancer | scheduled | "NCT06564324 (A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-01 (ESTIMATED); Lead Sponsor Nuvation Bio Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06564324)) |
| Jan to Apr 2029 | [IBTROZI (taletrectinib) topline data readout](https://sec-api.dev/pdufa/taletrectinib) | NUVB | Non Small Cell Lung Cancer | scheduled | "NCT06564324 (A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-01 (ESTIMATED); Lead Sponsor Nuvation Bio Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06564324)) |
| May 2029 | [Safusidenib primary completion](https://sec-api.dev/pdufa/safusidenib) | NUVB |  | scheduled | "NCT07712757 (Safety and Efficacy Study of Safusidenib in Participants With Grade 2 IDH1-Mutant Glioma): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2029-05 (ESTIMATED); Lead Sponsor Nuvation Bio Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07712757)) |
| May to Aug 2029 | [Safusidenib topline data readout](https://sec-api.dev/pdufa/safusidenib) | NUVB |  | scheduled | "NCT07712757 (Safety and Efficacy Study of Safusidenib in Participants With Grade 2 IDH1-Mutant Glioma): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2029-05 (ESTIMATED); Lead Sponsor Nuvation Bio Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07712757)) |
| Aug to Nov 2030 | [IBTROZI (taletrectinib) topline data readout](https://sec-api.dev/pdufa/taletrectinib) | NUVB | Non-small Cell Lung Cancer (NSCLC) | scheduled | "NCT07154706 (Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-08-30 (ESTIMATED); Lead Sponsor Nuvation Bio Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07154706)) |
| August 2030 | [IBTROZI (taletrectinib) primary completion](https://sec-api.dev/pdufa/taletrectinib) | NUVB | Non-small Cell Lung Cancer (NSCLC) | scheduled | "NCT07154706 (Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-08-30 (ESTIMATED); Lead Sponsor Nuvation Bio Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07154706)) |
| September 2030 | [Safusidenib primary completion](https://sec-api.dev/pdufa/safusidenib) | NUVB | Grade 2 IDH1-mutant Glioma; Grade 3 IDH1-mutant Glioma; Glioma | scheduled | "NCT07703436 (Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-09 (ESTIMATED); Lead Sponsor Nuvation Bio Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07703436)) |
| Sep to Dec 2030 | [Safusidenib topline data readout](https://sec-api.dev/pdufa/safusidenib) | NUVB | Grade 2 IDH1-mutant Glioma; Grade 3 IDH1-mutant Glioma; Glioma | scheduled | "NCT07703436 (Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-09 (ESTIMATED); Lead Sponsor Nuvation Bio Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07703436)) |

## Drugs

- [NUV-868](https://sec-api.dev/pdufa/nuv-868): advanced solid tumors to determine a maximum tolerated dose
- [Safusidenib](https://sec-api.dev/pdufa/safusidenib): Glioma, Grade 2 IDH1-mutant Glioma, Grade 2 Glioma (Astrocytoma or Oligodendroglioma) With an IDH1 Mutation
- [IBTROZI (taletrectinib)](https://sec-api.dev/pdufa/taletrectinib): with advanced ros1+ nsclc, advanced ros1+ nsclc, Non-small Cell Lung Cancer (NSCLC), Non Small Cell Lung Cancer
- [Ibtrozi (taletrectinib adipate)](https://sec-api.dev/pdufa/taletrectinib-adipate): To treat locally advanced or metastatic ROS1-positive non-small cell lung cancer

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/nuvb/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "NUVB catalysts: Nuvation Bio Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/nuvb/catalysts

```bibtex
@misc{secapidev_companies_nuvb_catalysts_20261116,
  title        = {NUVB catalysts: Nuvation Bio Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/nuvb/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_nuvb_catalysts_20261116","title":"NUVB catalysts: Nuvation Bio Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/nuvb/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
